RU2443412C2 - Высушенные восстановленные везикулы для фармацевтического применения - Google Patents

Высушенные восстановленные везикулы для фармацевтического применения Download PDF

Info

Publication number
RU2443412C2
RU2443412C2 RU2009117170/15A RU2009117170A RU2443412C2 RU 2443412 C2 RU2443412 C2 RU 2443412C2 RU 2009117170/15 A RU2009117170/15 A RU 2009117170/15A RU 2009117170 A RU2009117170 A RU 2009117170A RU 2443412 C2 RU2443412 C2 RU 2443412C2
Authority
RU
Russia
Prior art keywords
liposomes
lipid
active agent
protein
bmp
Prior art date
Application number
RU2009117170/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2009117170A (ru
Inventor
Клаус ХЕЛЛЕРБРАНД (DE)
Клаус ХЕЛЛЕРБРАНД
Андреас ШУТЦ (DE)
Андреас ШУТЦ
Райнер СИГЛ (DE)
Райнер СИГЛ
Original Assignee
Скил Текнолоджи Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Скил Текнолоджи Гмбх filed Critical Скил Текнолоджи Гмбх
Publication of RU2009117170A publication Critical patent/RU2009117170A/ru
Application granted granted Critical
Publication of RU2443412C2 publication Critical patent/RU2443412C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2009117170/15A 2006-10-06 2007-10-05 Высушенные восстановленные везикулы для фармацевтического применения RU2443412C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06021093.7 2006-10-06
EP06021093 2006-10-06

Publications (2)

Publication Number Publication Date
RU2009117170A RU2009117170A (ru) 2010-11-20
RU2443412C2 true RU2443412C2 (ru) 2012-02-27

Family

ID=38910893

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009117170/15A RU2443412C2 (ru) 2006-10-06 2007-10-05 Высушенные восстановленные везикулы для фармацевтического применения

Country Status (17)

Country Link
US (3) US20090297580A1 (https=)
EP (2) EP2081551B1 (https=)
JP (2) JP5484059B2 (https=)
KR (1) KR101333279B1 (https=)
CN (3) CN102940878A (https=)
CA (1) CA2664637C (https=)
CY (1) CY1113934T1 (https=)
DK (1) DK2081551T3 (https=)
ES (2) ES2400162T3 (https=)
HR (1) HRP20130328T1 (https=)
PL (1) PL2081551T3 (https=)
PT (1) PT2081551E (https=)
RS (1) RS52706B (https=)
RU (1) RU2443412C2 (https=)
SI (1) SI2081551T1 (https=)
TW (1) TWI455731B (https=)
WO (2) WO2008040557A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2725808C2 (ru) * 2014-12-18 2020-07-06 Бракко Суисс Са Состав нацеленных микровезикул, наполненных газом
RU2810788C2 (ru) * 2018-09-16 2023-12-28 ТиЭлСи БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, подходящие для суставной доставки, и их применение при лечении суставной боли

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6907884B2 (en) 2002-09-30 2005-06-21 Depay Acromed, Inc. Method of straddling an intraosseous nerve
US7258690B2 (en) 2003-03-28 2007-08-21 Relievant Medsystems, Inc. Windowed thermal ablation probe
US8361067B2 (en) 2002-09-30 2013-01-29 Relievant Medsystems, Inc. Methods of therapeutically heating a vertebral body to treat back pain
US7879103B2 (en) 2005-04-15 2011-02-01 Musculoskeletal Transplant Foundation Vertebral disc repair
US7959683B2 (en) 2006-07-25 2011-06-14 Musculoskeletal Transplant Foundation Packed demineralized cancellous tissue forms for disc nucleus augmentation, restoration, or replacement and methods of implantation
CA2957010C (en) 2008-09-26 2017-07-04 Relievant Medsystems, Inc. Systems and methods for navigating an instrument through bone
US10028753B2 (en) 2008-09-26 2018-07-24 Relievant Medsystems, Inc. Spine treatment kits
CA2790436A1 (en) 2010-02-18 2011-08-25 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products
SG10201502398RA (en) * 2010-04-27 2015-05-28 Scil Technology Gmbh Stable MIA/CD-RAP formulations
WO2013101772A1 (en) 2011-12-30 2013-07-04 Relievant Medsystems, Inc. Systems and methods for treating back pain
US20130202682A1 (en) * 2012-01-24 2013-08-08 The Trustees Of Columbia University In The City Of New York Synthetic matrix vesicles for biomimetic mineralization
SI2854769T1 (sl) * 2012-07-05 2023-09-29 Taiwan Liposome Company, Ltd. Postopki za zdravljenje artritisa
US10588691B2 (en) 2012-09-12 2020-03-17 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
CA2889478C (en) 2012-11-05 2020-11-24 Relievant Medsystems, Inc. Systems and methods for creating curved paths through bone and modulating nerves within the bone
US9724151B2 (en) 2013-08-08 2017-08-08 Relievant Medsystems, Inc. Modulating nerves within bone using bone fasteners
US10159646B2 (en) * 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US8986732B2 (en) 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
AU2016256979B2 (en) 2015-05-04 2021-01-28 Genfit Method for preparing transmembrane pH-gradient vesicles
CA2998665A1 (en) * 2015-09-18 2017-03-23 Bionet Pharma Gmbh Improvement of expression and folding in the manufacturing process of cd-rap by using a cd-rap precursor protein
US20190111178A1 (en) * 2016-04-04 2019-04-18 Gu Ventures Ab Methods and compositions for the treatment of intervertebral disc herniation
CA3061205A1 (en) * 2017-04-25 2018-11-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues
CN111182889A (zh) 2017-08-28 2020-05-19 美商Tlc生物医药公司 缓释麻醉剂组成物及其制备方法
WO2019055901A1 (en) 2017-09-18 2019-03-21 North Carolina State University ARTIFICIAL β CELLS AND METHODS OF USE
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
KR102058961B1 (ko) 2018-07-28 2019-12-24 주식회사 엑소코바이오 엑소좀의 동결건조 방법
KR102163806B1 (ko) * 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
HRP20240586T1 (hr) * 2018-10-09 2024-07-19 The University Of British Columbia Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima
EP4027912B1 (en) 2019-09-12 2024-12-18 Relievant Medsystems, Inc. Systems for tissue modulation
WO2022011115A1 (en) 2020-07-10 2022-01-13 Relievant Medsystems, Inc. Vertebral denervation in conjunction with vertebral fusion
US12082876B1 (en) 2020-09-28 2024-09-10 Relievant Medsystems, Inc. Introducer drill
AU2021409967A1 (en) 2020-12-22 2023-08-03 Relievant Medsystems, Inc. Prediction of candidates for spinal neuromodulation
US12433668B1 (en) 2021-11-08 2025-10-07 Relievant Medsystems, Inc. Impedance stoppage mitigation during radiofrequency tissue ablation procedures
CN113995852B (zh) * 2021-11-08 2024-01-30 河北大学 Arg-脂质体微囊、微囊包封的鱼精蛋白-siRNA复合体及其制备方法和应用
CN221431621U (zh) * 2023-07-10 2024-07-30 常州富谦生物科技有限公司 一种多层膜结构

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897353A (en) * 1986-03-13 1990-01-30 University Of Southwestern Louisiana Cryogenic protection of phosphofructokinase using amino acids and zinc ions
RU2000111523A (ru) * 1997-10-02 2002-05-10 Жан-Луи ДАССЕ Образование пептид/липидного комплекса путем совместной лиофилизации

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (https=) * 1977-08-05 1981-02-13 Battelle Memorial Institute
FR2416008A1 (fr) * 1978-02-02 1979-08-31 Oreal Lyophilisats de liposomes
IL79114A (en) 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
FR2591105B1 (fr) * 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
WO1992002208A1 (en) 1990-08-08 1992-02-20 Liposome Technology, Inc. Stable doxorubicin/liposome composition
CA2120197A1 (en) * 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
GB9320668D0 (en) 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
US6066331A (en) * 1994-07-08 2000-05-23 Barenholz; Yechezkel Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
IL115199A (en) * 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
AU5702099A (en) * 1998-09-01 2000-03-21 Millennium Pharmaceuticals, Inc. A novel protein related to melanoma-inhibiting protein and uses thereof
EP1025871A1 (en) * 1999-01-28 2000-08-09 F. Hoffmann-La Roche Ag Use of a melanoma inhibiting activity factor (MIA) for cartilage and bone repair
US7435260B2 (en) * 1999-08-13 2008-10-14 Ferree Bret A Use of morphogenetic proteins to treat human disc disease
ES2278648T3 (es) * 1999-12-06 2007-08-16 Warsaw Orthopedic, Inc. Dispositivo para tratar un disco intervertebral.
AU2002331481B2 (en) * 2001-10-03 2008-04-24 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
JP2006518701A (ja) * 2002-05-24 2006-08-17 ネオファーム、インコーポレイティッド カルジオリピン組成物、その製造方法及び使用
US7169405B2 (en) * 2003-08-06 2007-01-30 Warsaw Orthopedic, Inc. Methods and devices for the treatment of intervertebral discs
BRPI0509365B8 (pt) * 2004-03-30 2021-05-25 Ilypsa Inc composição farmacêutica, kit farmacêutico, e, uso da referida composição
EP1778309B1 (en) * 2004-05-21 2010-11-17 Synthes GmbH Replacement of nucleus pulposus using a hydrogel
CA2567405A1 (en) * 2004-05-25 2005-12-08 Stryker Corporation Use of morphogenic proteins for treating cartilage defects
EP1604693A1 (en) * 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
WO2006050327A2 (en) * 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
US20110071056A1 (en) * 2009-09-24 2011-03-24 Rajesh K Saini Degradable Surfactants, Including Degradable Gemini Surfactants, and Associated Methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897353A (en) * 1986-03-13 1990-01-30 University Of Southwestern Louisiana Cryogenic protection of phosphofructokinase using amino acids and zinc ions
RU2000111523A (ru) * 1997-10-02 2002-05-10 Жан-Луи ДАССЕ Образование пептид/липидного комплекса путем совместной лиофилизации

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
С.Kirby, G.Gregoriadis "Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes", BIOTECHNOLOGY, vol.2, №11, 1984, p.979-984. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2725808C2 (ru) * 2014-12-18 2020-07-06 Бракко Суисс Са Состав нацеленных микровезикул, наполненных газом
RU2810788C2 (ru) * 2018-09-16 2023-12-28 ТиЭлСи БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, подходящие для суставной доставки, и их применение при лечении суставной боли

Also Published As

Publication number Publication date
EP2086507A1 (en) 2009-08-12
PT2081551E (pt) 2013-02-18
RS52706B (sr) 2013-08-30
WO2008040556A1 (en) 2008-04-10
US20090297580A1 (en) 2009-12-03
CN101528197B (zh) 2013-02-13
CY1113934T1 (el) 2016-07-27
EP2086507B1 (en) 2018-11-07
KR20090086397A (ko) 2009-08-12
JP5404402B2 (ja) 2014-01-29
SI2081551T1 (sl) 2013-05-31
RU2009117170A (ru) 2010-11-20
WO2008040557A1 (en) 2008-04-10
US20090285880A1 (en) 2009-11-19
JP5484059B2 (ja) 2014-05-07
CN101528197A (zh) 2009-09-09
JP2010505482A (ja) 2010-02-25
EP2081551A1 (en) 2009-07-29
JP2010505785A (ja) 2010-02-25
ES2400162T3 (es) 2013-04-08
EP2081551B1 (en) 2013-01-23
DK2081551T3 (da) 2013-05-06
US20160220638A1 (en) 2016-08-04
HRP20130328T1 (hr) 2013-05-31
CN101605534A (zh) 2009-12-16
CN102940878A (zh) 2013-02-27
TW200829283A (en) 2008-07-16
TWI455731B (zh) 2014-10-11
ES2708851T3 (es) 2019-04-11
CA2664637A1 (en) 2008-04-10
KR101333279B1 (ko) 2013-11-27
PL2081551T3 (pl) 2013-06-28
CA2664637C (en) 2013-11-12
US9526761B2 (en) 2016-12-27

Similar Documents

Publication Publication Date Title
RU2443412C2 (ru) Высушенные восстановленные везикулы для фармацевтического применения
AU633078B2 (en) The use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions
JP5143538B2 (ja) タンパク質安定化調合物
US5977172A (en) PGE1 -containing-freeze dried preparation and process for the production thereof
ES2322974T3 (es) Formulaciones de igf-1 de cargas elevadas y reducidas en liposomas multivesiculares.
BR112012016459B1 (pt) composto farmacêutico parenteral de ação prolongada, composição farmacêutica e sal de glatirâmero farmaceuticamente aceitável
US20070254832A1 (en) Methods for the treatment of macular degeneration and related eye conditions
EP3238746B1 (en) High-density lipoprotein, and delivery of drug to posterior segment of eye by ocular instillation of said cytophilic peptide-fused high-density lipoprotein
JP2014521636A (ja) ペプチドおよびポリペプチド分子の制御放出のためのマトリクス組成物
KR20080044845A (ko) 철 킬레이트제를 포함하는 약학적 조성물
JP2937135B2 (ja) Ｐｇｅ１含有凍結乾燥製剤及び製法
US20090011980A1 (en) Method of Treating Parkinson's Disease in Humans by Direct Infusion of Glial Cell-Line Derived Neurotrophic Factor Into the Zona Incerta
Berillo et al. Review of recent advances in the use of drug delivery systems in ophthalmology
RU2211027C2 (ru) Способ конструирования, проверки и применения ассоциатов макромолекул и комплексных агрегатов с повышенной полезной нагрузкой и контролируемой степенью ассоциации/диссоциации
WO2007021822A2 (en) Compositions and methods of preparation of liposomal microparticulate il-12
JP2025526398A (ja) 末梢血管疾患を治療するための組成物及び方法
JPS61501686A (ja) リポソ−ム↓−ゲル組成物
WO1991007962A1 (fr) Emulsion de graisse
HK40017554A (en) Neuroprotective liposome compositions and methods for treatment of stroke

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20201006